Macrogenics Inc MGNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.08
- Day Range
- $3.79–4.24
- 52-Week Range
- $1.29–5.08
- Bid/Ask
- $3.75 / $4.37
- Shares Outstanding
- 63.70M
- Market Cap
- $268.24M
- Volume/Avg
- 851,459 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 293
- Website
- https://www.macrogenics.com
Valuation
|
Metric
|
MGNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.26 |
Price/Sales | 1.74 |
Price/Cash Flow | — |
Price/Earnings
MGNX
Financial Strength
|
Metric
|
MGNX
|
|---|---|
Quick Ratio | 2.92 |
Current Ratio | 2.96 |
Interest Coverage | −5.80 |
Quick Ratio
MGNX
Profitability
|
Metric
|
MGNX
|
|---|---|
Return on Assets (Normalized) | −16.89% |
Return on Equity (Normalized) | −96.74% |
Return on Invested Capital (Normalized) | −41.12% |
Return on Assets
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|><xlB## | LOCK|Nq@n | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<>SZ>vw | LOCK|!<<t | $83B | |||
| argenx SE ADR
ARGX
| LOCK|g!pq@@$ | LOCK|&ZG | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|bvrPqJhb | LOCK|BG>< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!!%Fjb | LOCK|B! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$%?zc%z | LOCK|hhys | $31B | |||
| Moderna Inc
MRNA
| LOCK|?>MdnX | LOCK|PR | $25B | |||
| Incyte Corp
INCY
| LOCK|#^V?vhS | LOCK|?w$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|XBKh!Dt | LOCK|>g | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|V@^#y@x | LOCK|@Z | $16B |
United States